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Abstract Lumbar herniated discs commonly occur in
patients 20–40 years of age, and result in acute symptoms
of shooting and intractable pain in the low back and/or
lower extremities. However, the prognosis of these patients
is considered to be very good. Moreover, 70 % of these
patients have been reported to be free from sciatica at
approximately 6 months after the first onset. Magnetic
resonance imaging (MRI) studies have described the
spontaneous resorption process of herniated discs, which is
a major cause of the reduction of symptoms in patients.
New advancements in MRI have recently been developed
that have facilitated the examination of nerve tract fibers
and identification of symptomatic nerve tissue. Further-
more, the mechanism underlying the resorption process of
a herniated disc has been determined. Inflammatory cyto-
kines such as TNF (tumor necrosis factor)-a, angiogenic
factors such as vascular endothelial growth factor, and
enzymes such as matrix metalloproteinases are intricately
related to each other. In our previous studies, matrix
metalloproteinase-7 (MMP-7) has been shown to play a
crucial role in the initiation of herniated disc resorption.
Therefore, we developed recombinant human MMP-7 for
intradiscal therapy through an industry–university joint
research program. We have already performed in vitro and
in vivo experiments to confirm its efficacy; this therapy
avoids the side effects associated with surgery, such as
nerve tissue damage. Moreover, the phase 1/2 studies of
recombinant human (rh) MMP-7 are currently ongoing in
the United States, and careful monitoring is required for
these clinical trials. In conclusion, patients with lumbar
herniated discs may benefit from the development of a less
invasive treatment for disc herniation, which can be
applied even immediately after the onset of disease
symptoms.
Introduction
Low back pain is the primary reason for patients visiting
physicians in Japan. This condition ranks second among
the complaints in the United States, following upper
respiratory tract complaints [1]. Herniated discs (HD)
account for 4 % of the total cases of mechanical low back
pain, and occur in approximately 2.8 million patients
annually [2]. Patients with lumbar HD experience acute
onset unilateral or bilateral lower extremity pain and
numbness associated with the low back pain [3]. However,
70 % of lumbar HD patients recover from sciatica within
6 weeks of its onset. Thus, considering the natural history
of HD, the overall patient prognosis is good. However, an
estimated 10 % of patients will experience continued pain
and neurological deficits, and surgical intervention should
be considered for these patients [1]. A systematic review
comparing surgical intervention and conservative man-
agement indicated that surgical intervention enables faster
pain relief, compared to prolonged conservative treatment,
during short-term follow-up, although no marked differ-
ences are noted during long-term follow-up [4, 5].
Lumbar HD patients are primarily between 20 and
40 years of age, employed, and play an active role in
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society. To reduce the quality of life issues caused by
surgical intervention, including microdiscectomy, more
effective and less invasive treatments—which require less
treatment time—need to be developed.
Molecular genetics and biology
Several previous studies have described the potential gene
markers for lumbar disc diseases, including collagen 9A2
[6, 7], vitamin D receptor [8], matrix metalloproteinase
(MMP)-3 [9], cartilage intermediate layer protein [10],
collagen 11A1 [11], thrombospondin (THBS2) [12], sickle
tail (SKT) [13], MMP-9 [12], asporin (ASPN) [14], and
carbohydrate sulfotransferase [15]. Systematic reviews
demonstrated that there is moderate evidence of correlation
of ASPN, COLXIA1, SKT, THBS2, and MMP-9 with HD
[16]. However, further studies are needed to identify the
gene that is strongly correlated with the disease. Assess-
ment of the upregulation and downregulation patterns of
specific candidate genes in animal models may facilitate
the identification their precise roles in disc degeneration.
Regenerative medicine techniques for the treatment of
disc degeneration have recently been developed for clinical
use. Co-culture of autologous mesenchymal stem cells with
the patient’s nucleus pulposus cells or annulus fibrosus
cells may be a good alternative for regenerating the
degenerated disc matrix [17]. In addition, the administra-
tion of autologous platelet-rich plasma may promote a
reparative effect on degenerative disc tissues [18]. These
methods suggest the potential for regeneration of degen-
erated disc tissues in the near future.
Development of image examination techniques
The resorption process of HD was demonstrated using
sequential magnetic resonance imaging (MRI), and this
resorption process may be the reason for the relatively
good prognosis in cases of HD (Fig. 1) [19]. Vroomen [20]
demonstrated that 70 % of patients with HD indicated the
disappearance of sciatica within 6 weeks of its onset. In
addition, the non-contained classification types of HD, such
as transligamentous extrusion and sequestration, as well as
the enhanced contrast noted around HD, indicated a high
tendency for resorption, thus suggesting that vasculariza-
tion around the HD would be an important factor for HD
resorption [21]. This HD resorption phenomenon was
demonstrated in the lumbar, thoracic, and cervical regions
of the spine [22, 23].
A recent study indicated that it was impossible to assess
good or unfavorable outcomes using MRI at the 1-year
follow-up for patients who had been treated for lumbar HD
[24]. However, with recent developments in MRI, the
observation of tract fibers with diffusion tensor tract ima-
ges [25] as well as the identification of symptomatic nerve
roots (due to spinal disorders) with diffusion-weighted
imaging, is currently possible [26]. Through these new
technological advancements in MRI, the identification of
symptomatic nerve tissues with HD will be possible in the
near future, thus facilitating more accurate investigations
for HD patients.
Surgery for HD
A study on HD due to disc rupture or cartilaginous tumor
was first reported in 1934. The study concluded that rup-
tures of the disc were more common than tumors. The
authors recommended that the primary mode of treatment
should be surgery. In 1939, Love described a surgical
technique that involved the identification of an HD mass
through myelography and subsequent removal of the HD
via partial laminectomy. A study on the long-term out-
comes of discectomy, including a follow-up period of more
than 10 years, showed relatively favorable results with an
average improvement rate of 73.5 % [27]. A prospective
randomized multicenter study was performed on 1,244
cases at 13 medical institutes in the United States to
compare whether surgical or conservative treatment
showed favorable outcomes [28]. When the Short Form 36
and Oswestry Disability Index (ODI) assessment was per-
formed at 3 months, 1 year, and 2 years after intervention,
surgical treatment was found to be more effective. How-
ever, the findings of that study should be cautiously inter-
preted, as the crossover rates between the surgery and
conservative group were 40 and 45 %, respectively.
The first case of the use of the microendoscopic disc-
ectomy system in Japan involved a patient with lumbar HD
in 1998. Since then, the use of minimally invasive spinal
T2 Contrast-enhanced
1st visit
3 months
later
Fig. 1 Sequential magnetic resonance imaging of a 66 year-old man
demonstrating resorption of the herniated disc
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endoscopic surgery has increased rapidly, according to an
annual report by the Japanese Orthopaedic Association. A
prospective study was performed on 120 consecutive
patients with lumbar HD treated by the lumbar MED sys-
tem, with a 5-year follow-up period; the authors indicated
that this less invasive and efficient approach using a small
skin incision ensured minimal tissue damage and a shorter
length of hospital stay, as well as excellent clinical out-
comes (ODI and lumbar visual analogue scale scoring), as
compared to conventional discectomy [29]. Cases of
intraoperative dural tears, surgery at the wrong disc level,
and contralateral symptoms owing to the lack of complete
decompression of the nerve root were mainly reported for
operations performed by inexperienced surgeons, although
the frequency decreased with increasing experience of the
operator [30]. However, cases of postoperative epidural
hematomas, nerve root anomalies, and mechanical failures
of surgical instruments were noted even in operations
performed by experienced surgeons [30].
Mechanism of HD resorption
The classical definition of HD is a protrusion or extrusion
of a degenerated disc, which results in the presence of a
low amount of disc matrix components such as proteo-
glycan and type II collagen in the spinal canal or neural
foramen, where there is abundant vascular supply. Surgi-
cally removed tissues indicated tissue granulation, along
with the marked infiltration of macrophages and some
lymphocytes, concomitant with neovascularization [31].
We developed a co-culture model of disc chondrocytes and
peritoneum macrophages derived from MMP-3- or MMP-
7-deficient mice to reproduce the acute phase of HD and
investigate the role in MMPs in HD resorption. The MMP-
3 derived from disc chondrocytes plays a crucial role in the
generation of a macrophage chemoattractant, which results
in the subsequent infiltration of active macrophages into
disc tissues [32]. In addition, the MMP-7 released by
macrophages is essential for the release of soluble TNF-a
from these macrophages [33]. Thus, extensive communi-
cation between disc chondrocytes and extrinsic infiltrated
macrophages is important for HD resorption.
Vascular endothelial growth factor (VEGF), a potent
angiogenic factor, was found to be strongly expressed in
surgical samples of lumbar HD. We previously reported
that the upregulation of VEGF under co-culture conditions
strongly induced neovascularization [34]. TNF-a induces
the release of VEGF from disc cells through NF-kB sig-
naling, which results in CD31 expression on endothelial
cells and formation of an anastomosing network [35].
Interestingly, the degree of angiogenic activity was found
to be closely related to aging.
Monocyte chemotactic protein (MCP)-1 is a CC che-
mokine that plays an important role in the activation and
recruitment of macrophages. MCP-1 was found to be
expressed in both infiltrated macrophages and disc cells
from surgical HD samples [36]. Moreover, TNF-a acts as
the initiator of inflammation, following contact between
macrophages and disc chondrocytes [37]. TNF-a induces
the release of thymic stromal lymphopoietin (TSLP) from
disc cells through the NF-kB pathway [38]. The disc cells
then express the TSLP receptor and produce MCP-1
through the phosphatidyl-inositol 3-kinase/Akt pathway.
Interestingly, MCP-1 expression in murine intervertebral
discs showed age-related decreases, whereas its response to
inflammation showed age-related changes.
Tumor necrosis factor-like weak inducer of apoptosis
(TWEAK) is a member of the TNF-a superfamily of
cytokines. The TWEAK and its receptor, Fn14, were
expressed in disc tissues [39]. The TWEAK-induced disc
cells to generate MMP-3 via a c-Jun N-terminal kinase,
resulting in disc matrix degradation. TWEAK also stimu-
lated MCP-1 through the NF-kB pathway (Fig. 2) [40, 41].
Development of a less invasive treatment for HD
Lumbar HD commonly occurs in patients aged
20–40 years with active lifestyles. These patients show
acute onset of low back and/or lower extremity pain, which
results in absenteeism from daily work. Thus, a less inva-
sive treatment compared to microdiscectomy with
microscopy or endoscopy is required.
Chemonucleolysis is a treatment that involves the
administration of enzymes into the HD, and has been
proposed as an alternative and less invasive approach to
avoid surgery. Chemonucleolysis causes the degradation of
aggrecan and/or collagens, which results in the decrease of
the HD matrix and water content, as well as a reduction in
the pressure exerted by the HD on nerve tissues. Smith
previously reported on the administration of chymopapain,
derived from Carica papaya, into lumbar HD. Although its
therapeutic effects have been well documented, chymopa-
pain contains a wide range of substrates, such as aggrecan
and collagens, which can lead to certain adverse side
effects, including anaphylactic shock, subarachnoid hem-
orrhage, transverse myelitis, and discitis. Purified bacterial
collagenase, derived from Clostridium histolyticum, has
also been used for chemonucleolysis. A prospective ran-
domized study using chymopapain and collagenase showed
good and excellent outcomes 5 years after treatment in
72 % of the chymopapain group and in 52 % of the col-
lagenase group [42]. In addition, a prospective randomized
trial of 100 consecutive lumbar HD patients was performed
to determine whether chemonucleolysis with chymopapain
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or standard discectomy showed better or improved out-
comes. It was found that there were no differences between
the two treatments at 1, 10–13, and 24–27 years after the
treatment [43]. Thus, chymopapain—which had been rec-
ognized as a favorable chemonucleolysis reagent—was
subsequently withdrawn as a treatment option owing to the
associated complications.
We demonstrated that MMP-7, which is strongly
expressed in human HD material, plays a crucial role in the
HD resorption process [32]. Therefore, we developed
recombinant human (rh) MMP-7, which may be an ideal
candidate as a chemonucleolysis drug. rhMMP-7 degraded
human surgical samples of HD in a concentration-depen-
dent manner [44]. Moreover, this effect is not significantly
correlated with patient age, HD degeneration grade, and
interval between the onset of symptoms and surgery. The
aggrecan cleavage rates of rhMMP-7 exhibited a 1,000-
fold increase when compared to that of type 1 or type 2
collagens [44]. The intradiscal administration of rhMMP-7
was found to decrease the proteoglycan and water content
Fig. 2 Schematic model
demonstrating the mechanism
of herniated disc resorption.
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in a canine vivo model [44]. Moreover, epidural injections
of rhMMP-7 did not show any adverse effects at both the
injection site and nerve tissues [44]. Thus, rhMMP-7 may
be a novel chemonucleolysis agent (Fig. 3). We are cur-
rently performing clinical trials using rhMMP-7 on lumbar
HD patients in the United States and are carefully moni-
toring the patients’ conditions.
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